Objective:Curcumin(Cur)and Chitosan(CS)were utilized as primary components for the production of curcumin chitosan nanoparticles.The impact of these nanoparticles on oxidative stress in mycoplasma pneumoniae-infected ...Objective:Curcumin(Cur)and Chitosan(CS)were utilized as primary components for the production of curcumin chitosan nanoparticles.The impact of these nanoparticles on oxidative stress in mycoplasma pneumoniae-infected mice was assessed.Methods:The drug loading and entrapment efficiency of Cur-CS nanoparticles were determined for various feeding ratios,and the release profiles of Cur-CS nanoparticles in different release media were investigated using the dynamic membrane dialysis method.The mycoplasma pneumoniae pneumonia(MPP)mouse model was created through the infection of mice with mycoplasma pneumoniae.The mice were then allocated randomly into five groups:a blank control group,an MPP model group,a low Cur-CS dose group,a middle Cur-CS dose group,and a high Cur-CS dose group,each consisting of 7 mice.The study compared the levels of antioxidant enzymes and phospholipid peroxide content in the lung tissue of mice across various experimental groups.Results:The findings indicated that the drug loading of nanoparticles escalated from 2.10%to 11.74%as the feed ratio of Cur to CS increased from 1∶20 to 1∶2.5.Concurrently,as drug loading increased,the entrapment efficiency of nanoparticles decreased from 85.33%to 58.92%.The cumulative release rate of Cur was 95.3%after 24 h,whereas the cumulative release rate of Cur-CS nanoparticles was only 94.3%after 48 h.Analysis of the lung tissue samples indicated that the levels of SOD[(76.17±9.36)U/ml,(86.23±10.09)U/ml,(98.06±11.12)U/ml]and GSH-Px[(19.75±2.22)U/ml,(23.92±2.53)U/ml,(27.23±2.67)U/ml]were significantly higher than those in the MPP model group(P<0.05).Conclusion:This suggests that curcumin chitosan nanoparticles may be suitable for antioxidant treatment of mycoplasma pneumoniae in mice,and can dose-dependently inhibit the release of oxygen free radicals in the lung tissue of MPP mice.This finding may offer a new avenue for the development of therapeutic drug carriers for MPP.展开更多
文摘Objective:Curcumin(Cur)and Chitosan(CS)were utilized as primary components for the production of curcumin chitosan nanoparticles.The impact of these nanoparticles on oxidative stress in mycoplasma pneumoniae-infected mice was assessed.Methods:The drug loading and entrapment efficiency of Cur-CS nanoparticles were determined for various feeding ratios,and the release profiles of Cur-CS nanoparticles in different release media were investigated using the dynamic membrane dialysis method.The mycoplasma pneumoniae pneumonia(MPP)mouse model was created through the infection of mice with mycoplasma pneumoniae.The mice were then allocated randomly into five groups:a blank control group,an MPP model group,a low Cur-CS dose group,a middle Cur-CS dose group,and a high Cur-CS dose group,each consisting of 7 mice.The study compared the levels of antioxidant enzymes and phospholipid peroxide content in the lung tissue of mice across various experimental groups.Results:The findings indicated that the drug loading of nanoparticles escalated from 2.10%to 11.74%as the feed ratio of Cur to CS increased from 1∶20 to 1∶2.5.Concurrently,as drug loading increased,the entrapment efficiency of nanoparticles decreased from 85.33%to 58.92%.The cumulative release rate of Cur was 95.3%after 24 h,whereas the cumulative release rate of Cur-CS nanoparticles was only 94.3%after 48 h.Analysis of the lung tissue samples indicated that the levels of SOD[(76.17±9.36)U/ml,(86.23±10.09)U/ml,(98.06±11.12)U/ml]and GSH-Px[(19.75±2.22)U/ml,(23.92±2.53)U/ml,(27.23±2.67)U/ml]were significantly higher than those in the MPP model group(P<0.05).Conclusion:This suggests that curcumin chitosan nanoparticles may be suitable for antioxidant treatment of mycoplasma pneumoniae in mice,and can dose-dependently inhibit the release of oxygen free radicals in the lung tissue of MPP mice.This finding may offer a new avenue for the development of therapeutic drug carriers for MPP.
